Growens Valuation

Is GROW undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GROW when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate GROW's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate GROW's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for GROW?

Key metric: As GROW is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for GROW. This is calculated by dividing GROW's market cap by their current revenue.
What is GROW's PS Ratio?
PS Ratio1x
Sales€76.33m
Market Cap€74.58m

Price to Sales Ratio vs Peers

How does GROW's PS Ratio compare to its peers?

The above table shows the PS ratio for GROW vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.5x
AIW Almawave
1.5x11.3%€78.0m
EXAI Expert.ai
4.2x10.2%€139.0m
SYS SYS-DAT
3x13.9%€165.5m
MAPS Maps
1.2x9.4%€37.3m
GROW Growens
1x7.3%€74.6m

Price-To-Sales vs Peers: GROW is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (2.5x).


Price to Sales Ratio vs Industry

How does GROW's PS Ratio compare vs other companies in the European Software Industry?

44 CompaniesPrice / SalesEstimated GrowthMarket Cap
GROW 1.0xIndustry Avg. 2.0xNo. of Companies47PS0246810+
44 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: GROW is good value based on its Price-To-Sales Ratio (1x) compared to the European Software industry average (2x).


Price to Sales Ratio vs Fair Ratio

What is GROW's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GROW PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1x
Fair PS Ratio1x

Price-To-Sales vs Fair Ratio: GROW is good value based on its Price-To-Sales Ratio (1x) compared to the estimated Fair Price-To-Sales Ratio (1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GROW forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€5.88
€6.85
+16.5%
6.6%€7.30€6.40n/a2
Nov ’25€5.98
€6.85
+14.5%
6.6%€7.30€6.40n/a2
Oct ’25€5.36
€6.95
+29.7%
5.0%€7.30€6.60n/a2
Sep ’25€7.24
€6.95
-4.0%
5.0%€7.30€6.60n/a2
Aug ’25€7.48
€6.80
-9.1%
2.9%€7.00€6.60n/a2
Jul ’25€7.06
€6.80
-3.7%
2.9%€7.00€6.60n/a2
Jun ’25€6.92
€6.88
-0.5%
2.9%€7.05€6.60n/a3
May ’25€7.34
€6.82
-7.1%
4.3%€7.05€6.40n/a3
Apr ’25€6.18
€7.05
+14.1%
0.6%€7.10€7.00n/a3
Mar ’25€5.20
€7.05
+35.6%
0.6%€7.10€7.00n/a3
Feb ’25€5.28
€7.05
+33.5%
0.6%€7.10€7.00n/a3
Jan ’25€5.32
€7.15
+34.4%
1.5%€7.30€7.05n/a3
Dec ’24€6.34
€7.15
+12.8%
1.5%€7.30€7.05n/a3
Nov ’24€6.50
€7.28
+12.1%
2.5%€7.50€7.05€5.983
Oct ’24€6.46
€7.27
+12.5%
2.8%€7.50€7.00€5.363
Sep ’24€6.56
€7.20
+9.8%
4.1%€7.50€6.80€7.243
Aug ’24€6.34
€7.20
+13.6%
4.1%€7.50€6.80€7.483
Jul ’24€6.40
€7.07
+10.4%
4.4%€7.50€6.80€7.063
Jun ’24€5.56
€7.07
+27.1%
4.4%€7.50€6.80€6.923
May ’24€5.74
€7.07
+23.1%
4.4%€7.50€6.80€7.343
Apr ’24€6.00
€6.85
+14.2%
0.7%€6.90€6.80€6.182
Mar ’24€5.72
€6.85
+19.8%
0.7%€6.90€6.80€5.202
Feb ’24€4.29
€5.43
+26.7%
7.7%€6.00€5.00€5.283
Jan ’24€4.29
€5.43
+26.7%
7.7%€6.00€5.00€5.323
Dec ’23€3.83
€5.43
+41.9%
7.7%€6.00€5.00€6.343
Nov ’23€4.33
€5.80
+33.9%
10.2%€6.40€5.00€6.503

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies